ReviewJACC. Heart failure2025
Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection Fraction.
Review in JACC. Heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression.Basic research in cardiology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
Abstract
Heart failure with preserved ejection fraction (HFpEF) has risen to become the most common form of heart failure (HF) worldwide. The pathophysiology of HFpEF is complex and intimately tied to cardiac-metabolic-kidney abnormalities, spanning cardiac, vascular, and noncardiovascular organ systems. Large-scale prospective phenotyping studies that comprehensively examine these abnormalities in the same patient are not available, an evidence gap recognized by a NHLBI (National Heart, Lung, and Blood Institute)-assembled working group of experts as a major bottleneck impeding new therapeutic innovations. Here, we present the rationale and design for the HeartShare/AMP-HF (Accelerating Medicines Partnership-Heart Failure) program, supported through the NHLBI, the FNIH (Foundation for the National Institutes of Health), the U.S. FDA (Food and Drug Administration), and multiple industry and nonprofit partners.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.